Stocksigma LogoStocksigma Logo

Wanbury Receives ANVISA Approval for Metformin HCl API

Wanbury Limited secured regulatory approval (CADIFA: Letter of Suitability for API) from Brazil's ANVISA for its flagship product, Metformin HCl EP grade

Wanbury Receives ANVISA Approval for Metformin HCl API

Wanbury Ltd 路 Press Release 路 12 Nov 2026, 4:57 pm

Wanbury Receives ANVISA Approval for Metformin HCl API Wanbury Limited secured regulatory approval (CADIFA: Letter of Suitability for API) from Brazil's ANVISA for its flagship product, Metformin HCl EP grade, on 12th Nov'26. Marking the company's third consecutive ANVISA approval, this clearance enables pharmaceutical customers to utilize Wanbury's API for formulation manufacturing in Brazil. Following the approval, the company has initiated commercial discussions with multiple clients to scale up business volumes in the region.

Original exchange filing (PDF)

More announcements from Wanbury Ltd

All Wanbury Ltd announcements